04 December 2024
04 December 2024
A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Biomunex could receive up to $610m, including upfront and milestone payments.
Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.
The increased value of the Euro for pharmaceutical pricing purposes will likely result in a corresponding rise in drug prices.
Takeda will make an upfront payment of $200m to Keros.
The transaction is valued at $2.6bn equity value and $2.5bn net of cash.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
